Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2004. The report details a share repurchase transaction executed on August 13, 2004, and updates regarding directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,062.78 pence per share.
- Treasury Holdings: 33,718,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,900,329,461 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 1,000,000 shares. Additionally, the GlaxoSmithKline US Retirement Savings Plan reported a decrease in Ordinary Share ADRs held from 19,179,793 to 19,162,092 due to fund movements on August 12, 2004, at an average price of $40.18.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,062.78 pence.
- Confirm the updated total share count and Treasury holdings as of August 13, 2004.
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the US Retirement Savings Plan, which saw a slight reduction in ADR holdings.
- Recognize that this filing does not contain quarterly or annual financial performance data.